Consequently, a nomogram combining KPS, extent of resection, chemoradiotherapy, MGMT, and the mFS was developed to examine the potential of these factors in predicting 0.5‐, 1‐, and 2‐year survival in patients with GBM (Figure 5A). The gene discussed is MGMT; the disease is glioblastoma.